Evidence map›Paper›PMID 35319388›Full record

ReviewReviews on recent clinical trials2022

Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3.

Yulia Pastukhova, Francesco Luzza, Sviatoslav Shevel, Oleksii Savchuk, Liudmyla Ostapchenko, Tetyana Falalyeyeva, Nataliia Molochek, Olena Kuryk, Oleksandr Korotkyi, Nazarii Kobyliak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Reviews on recent clinical trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yulia PastukhovaTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Francesco LuzzaUniversity Magna Graecia of Catanzaro, Catanzaro, Italy.
Sviatoslav ShevelTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Oleksii SavchukTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Liudmyla OstapchenkoTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Tetyana FalalyeyevaTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Nataliia MolochekTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Olena KurykBogomolets National Medical University, Kyiv, Ukraine.
Oleksandr KorotkyiTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Nazarii KobyliakBogomolets National Medical University, Kyiv, Ukraine.
Taras Shevchenko National University of Kyiv · UABogomolets National Medical University · UAKyiv City Clinical Oncology Center · UAMagna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes is a metabolic disease characterized by hyperglycemia as a result of insulin resistance and decreased insulin secretion. A relatively large number of patients with this type of diabetes have abdominal obesity, which also affects insulin resistance development. Chronic hyperglycemia can lead to damage and dysfunction of various organs, and a striking example is diabetic nephropathy. Diabetic nephropathy is a specific kind of kidney damage that occurs due to complications of diabetes and is accompanied by the formation of diffuse or nodular glomerulosclerosis, which can lead to terminal renal failure and requires immediate substitution through renal therapy or renal transplantation. Diabetic nephropathy is diagnosed with albuminuria and a decrease in the rate of glomerular filtration.

methodsThis review was based on a literature search for the most important evidence of vitamin D as a possible method of prevention for obesity, type 2 diabetes, and diabetic nephropathy. Collected published articles were summarized according to their overall themes.

resultsIn this review, we considered vitamin D as a possible method of treatment for type 2 diabetes, as well as its complications, including diabetic nephropathy.

conclusionStudies show that vitamin D inhibits the renin-angiotensin-aldosterone system, resulting in improved renal function in diabetic nephropathy. Vitamin D also has antiinflammatory, antiproliferative, and anti-metastatic effects, which improve endothelial function.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesHyperglycemiaInsulin ResistanceHumansVitamin DVitamin Ddiabetic nephropathyhyperglycemiametabolic changesrenin-angiotensin-aldosterone systemtype 2 diabetesVitamin D

Identifiers

PMID35319388
OpenAlexW4220964451

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.